Dry Eye Syndrome Drugs Market to grow by USD 2,159.21 million from 2022 to 2027; The growing geriatric population drives the market - Technavio

NEW YORK, Aug. 9, 2023 /PRNewswire/ -- The dry eye syndrome drugs market is set to grow by USD 2,159.21 million from 2022 to 2027 progressing at a CAGR of 6.53% during the forecast period. The report offers an up-to-date analysis regarding the current global market scenario, the latest trends and drivers, and the overall market environment. The growing geriatric population is a major factor notably driving the dry eye syndrome market growth. Dry eye syndrome occurs when tear production is insufficient or when tears evaporate too quickly. It is more common among the elderly, and the likelihood of developing the condition rises with age. Asia is a highly attractive market due to its rapidly growing geriatric population, while North America and Europe dominate with significant investments in healthcare. Dry eye syndrome is closely linked to age, as tear production decreases as individuals get older, particularly for those aged 50 years and above, as reported by the National Institutes of Health (NIH). Factors like altered reflex secretion, lacrimal gland dysfunction, inflammatory damage to lacrimal glands, or reduced corneal sensitivity may lead to tear deficiency, resulting in dry eye syndrome. The use of topical medications is also associated with an increased risk of dry eyes. These factors are expected to propel market growth during the forecast period.  -Here is an Exclusive report talking about Market scenarios with a historical period (2017-2021) and forecast period (2023-2027). Download Sample Report in minutes!

The dry eye syndrome drugs market covers the following areas:

• Dry Eye Syndrome Drugs Market Sizing
• Dry Eye Syndrome Drugs Market Forecast
• Dry Eye Syndrome Drugs Market Analysis

Dry Eye Syndrome Drugs Market 2023-2027 - Market Dynamics

Trends

Advancements in drug delivery technologies are an emerging trend shaping market growth. In recent times, significant progress has been made in drug delivery systems to enhance the effectiveness and convenience of treating dry eye syndrome. These advancements aim to overcome challenges associated with conventional eye drops, such as limited effectiveness, patient non-compliance, and inconsistent dosing. Lipid-based formulations have been developed to mimic natural tears, providing stability to the tear film and reducing tear evaporation. Additionally, sustained-release drug delivery systems like hydrogels, inserts, and punctal plugs enable controlled and prolonged drug release. Nanoparticles and nanomicelles have also been utilized to encapsulate therapeutic agents, protecting them from degradation and facilitating better penetration into ocular tissues. These innovations in drug delivery technologies are expected to drive the growth of the dry eye syndrome drugs market in the coming years.

Challenges 

The presence of strong substitutes for treating dry eye syndrome is a significant challenge hindering market growth. Apart from medications, various treatment options are available for dry eyes, including surgical procedures and nutritional supplements. Some patients with severe corneal injuries resulting in vision loss may opt for advanced surgical techniques, such as using salivary glands as an alternative for tears. Another innovative surgical approach is the minor gland salivary auto transplant, which has shown promise in studies. Additionally, punctual occlusion is a non-therapeutic treatment for dry eye syndrome, involving small plugs that seal the tear ducts to maintain eye moisture. The increasing adoption of these alternative treatment options is expected to impact the revenue growth of the dry eye syndrome drugs market in the forecast period.

What's New? -

• Special coverage on the Russia-Ukraine war; global inflation; recovery analysis from COVID-19; supply chain disruptions, global trade tensions; and risk of recession
• Global competitiveness and key competitor positions
• Market presence across multiple geographical footprints - Strong/Active/Niche/Trivial - Buy the report!

Dry Eye Syndrome Drugs Market 2023-2027: Market Segmentation

This dry eye syndrome drugs market report extensively covers market segmentation by distribution channel (retail pharmacies, hospital pharmacies, and online pharmacies), product (OTC drugs and prescription drugs), and geography (North America, Europe, Asia, and Rest of World (ROW)).

• The market share growth by the retail pharmacies segment will be significant during the forecast period. Retail pharmacies play a crucial role in the distribution and accessibility of dry eye syndrome drugs for consumers. They act as convenient points of contact for patients seeking over-the-counter or prescription medications to manage dry eye symptoms. These pharmacies, including independent and chain pharmacies and drugstore retailers, offer a wide range of dry eye syndrome drugs, such as artificial tears, ointments, gels, and prescription medications. Patients can receive guidance from pharmacists on selecting and using the appropriate dry eye medications. Retail pharmacies cater to patients who prefer in-person assistance, immediate availability, and personalized recommendations. Patients can discuss their symptoms and concerns with pharmacists and purchase suitable dry eye syndrome drugs based on their individual needs. These factors are expected to drive the growth of the retail pharmacy segment during the forecast period.

This report presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources through an analysis of key parameters- View Sample Report

Companies Mentioned

• Abbott Laboratories
• AbbVie Inc.
• AFT Pharmaceuticals Ltd.
• Akorn Operating Co. LLC
• Bausch Health Co. Inc.
• F. Hoffmann La Roche Ltd.
• GlaxoSmithKline Plc
• I MED Pharma Inc.
• Johnson and Johnson Services Inc.
• Laboratoires THEA SAS
• Mitotech SA
• Novaliq GmbH
• Novartis AG
• Oasis Medical Inc.
• Otsuka Holdings Co. Ltd.
• Santen Pharmaceutical Co. Ltd.
• Sentiss Pharma Pvt. Ltd.
• Sun Pharmaceutical Industries Ltd.
• Viatris Inc.
• Visufarma

Company Offering 

• Abbott Laboratories - The company offers dry eye syndrome drugs such as Lacrisyn. 
• AbbVie Inc. - The company offers dry eye syndrome drugs such as Restasis.
• AFT Pharmaceuticals Ltd. - The company offers dry eye syndrome drugs such as NovaTears.

Register for a trial today and gain instant access to 17,000+ market research reports.

Technavio's SUBSCRIPTION platform

Related Reports:

The allergy relieving eye drops market share is expected to increase by USD 354.94 million from 2021 to 2026, and the market's growth momentum will accelerate at a CAGR of 4.31%. This report extensively covers allergy relieving eye drops market segmentation by product (antihistamines, non-steroidal anti-Inflammatory drugs, vasoconstrictors, and others) and Geography (North America, Europe, Asia, and Rest of World (ROW)). The high prevalence and incidence of eye infections is a major factor driving the global allergy relieving eye drops market share growth.

The artificial eye market share is expected to increase by USD 34,140.17 thousand from 2021 to 2026, and the market's growth momentum will accelerate at a CAGR of 8.16%. This report extensively covers artificial eye market segmentation by product (integrated prosthetic eye, non-integrated prosthetic eye, and retinal prosthetics) and geography (North America, Europe, Asia, and Rest of World (ROW)). Increasing demand for custom-made ocular prosthesis is one of the key artificial eye market trends contributing to the market growth. 

Key Topics Covered:

1 Executive Summary

• 1.1 Market overview 
• Exhibit 01: Executive Summary – Chart on Market Overview
• Exhibit 02: Executive Summary – Data Table on Market Overview
• Exhibit 03: Executive Summary – Chart on Global Market Characteristics
• Exhibit 04: Executive Summary – Chart on Market by Geography
• Exhibit 05: Executive Summary – Chart on Market Segmentation by Distribution Channel
• Exhibit 06: Executive Summary – Chart on Market Segmentation by Product
• Exhibit 07: Executive Summary – Chart on Incremental Growth
• Exhibit 08: Executive Summary – Data Table on Incremental Growth
• Exhibit 09: Executive Summary – Chart on Vendor Market Positioning

2 Market Landscape

• 2.1 Market ecosystem 
• Exhibit 10: Parent market
• Exhibit 11: Market Characteristics

3 Market Sizing

• 3.1 Market definition 
• Exhibit 12: Offerings of vendors included in the market definition

• 3.2 Market segment analysis 
• Exhibit 13: Market segments

• 3.3 Market size 2022 

• 3.4 Market outlook: Forecast for 2022-2027
• Exhibit 14: Chart on Global - Market size and forecast 2022-2027 ($ million)
• Exhibit 15: Data Table on Global - Market size and forecast 2022-2027 ($ million)
• Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
• Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)

4 Historic Market Size

• 4.1 Global dry eye syndrome drugs market 2017 - 2021
• Exhibit 18: Historic Market Size – Data Table on global dry eye syndrome drugs market 2017 - 2021 ($ million)

• 4.2 Distribution Channel Segment Analysis 2017 - 2021
• Exhibit 19: Historic Market Size – Distribution Channel Segment 2017 - 2021 ($ million)

• 4.3 Product Segment Analysis 2017 - 2021
• Exhibit 20: Historic Market Size – Product Segment 2017 - 2021 ($ million)

• 4.4 Geography Segment Analysis 2017 - 2021
• Exhibit 21: Historic Market Size – Geography Segment 2017 - 2021 ($ million)

• 4.5 Country Segment Analysis 2017 - 2021
• Exhibit 22: Historic Market Size – Country Segment 2017 - 2021 ($ million)

5 Five Forces Analysis

• 5.1 Five forces summary 
• Exhibit 23: Five forces analysis - Comparison between 2022 and 2027

• 5.2 Bargaining power of buyers 
• Exhibit 24: Chart on Bargaining power of buyers – Impact of key factors 2022 and 2027

• 5.3 Bargaining power of suppliers 
• Exhibit 25: Bargaining power of suppliers – Impact of key factors in 2022 and 2027

• 5.4 Threat of new entrants 
• Exhibit 26: Threat of new entrants – Impact of key factors in 2022 and 2027

• 5.5 Threat of substitutes 
• Exhibit 27: Threat of substitutes – Impact of key factors in 2022 and 2027

• 5.6 Threat of rivalry 
• Exhibit 28: Threat of rivalry – Impact of key factors in 2022 and 2027

• 5.7 Market condition 
• Exhibit 29: Chart on Market condition - Five forces 2022 and 2027

6 Market Segmentation by Distribution Channel

• 6.1 Market segments 
• Exhibit 30: Chart on Distribution Channel - Market share 2022-2027 (%)
• Exhibit 31: Data Table on Distribution Channel - Market share 2022-2027 (%)

• 6.2 Comparison by Distribution Channel 
• Exhibit 32: Chart on Comparison by Distribution Channel
• Exhibit 33: Data Table on Comparison by Distribution Channel

• 6.3 Retail pharmacies - Market size and forecast 2022-2027 
• Exhibit 34: Chart on Retail pharmacies - Market size and forecast 2022-2027 ($ million)
• Exhibit 35: Data Table on Retail pharmacies - Market size and forecast 2022-2027 ($ million)
• Exhibit 36: Chart on Retail pharmacies - Year-over-year growth 2022-2027 (%)
• Exhibit 37: Data Table on Retail pharmacies - Year-over-year growth 2022-2027 (%)

• 6.4 Hospital pharmacies - Market size and forecast 2022-2027 
• Exhibit 38: Chart on Hospital pharmacies - Market size and forecast 2022-2027 ($ million)
• Exhibit 39: Data Table on Hospital pharmacies - Market size and forecast 2022-2027 ($ million)
• Exhibit 40: Chart on Hospital pharmacies - Year-over-year growth 2022-2027 (%)
• Exhibit 41: Data Table on Hospital pharmacies - Year-over-year growth 2022-2027 (%)

• 6.5 Online pharmacies - Market size and forecast 2022-2027 
• Exhibit 42: Chart on Online pharmacies - Market size and forecast 2022-2027 ($ million)
• Exhibit 43: Data Table on Online pharmacies - Market size and forecast 2022-2027 ($ million)
• Exhibit 44: Chart on Online pharmacies - Year-over-year growth 2022-2027 (%)
• Exhibit 45: Data Table on Online pharmacies - Year-over-year growth 2022-2027 (%)

• 6.6 Market opportunity by Distribution Channel
• Exhibit 46: Market opportunity by Distribution Channel ($ million)
• Exhibit 47: Data Table on Market opportunity by Distribution Channel ($ million)

7 Market Segmentation by Product

• 7.1 Market segments 
• Exhibit 48: Chart on Product - Market share 2022-2027 (%)
• Exhibit 49: Data Table on Product - Market share 2022-2027 (%)

• 7.2 Comparison by Product 
• Exhibit 50: Chart on Comparison by Product
• Exhibit 51: Data Table on Comparison by Product

• 7.3 OTC drugs - Market size and forecast 2022-2027
• Exhibit 52: Chart on OTC drugs - Market size and forecast 2022-2027 ($ million)
• Exhibit 53: Data Table on OTC drugs - Market size and forecast 2022-2027 ($ million)
• Exhibit 54: Chart on OTC drugs - Year-over-year growth 2022-2027 (%)
• Exhibit 55: Data Table on OTC drugs - Year-over-year growth 2022-2027 (%)

• 7.4 Prescription drugs - Market size and forecast 2022-2027 
• Exhibit 56: Chart on Prescription drugs - Market size and forecast 2022-2027 ($ million)
• Exhibit 57: Data Table on Prescription drugs - Market size and forecast 2022-2027 ($ million)
• Exhibit 58: Chart on Prescription drugs - Year-over-year growth 2022-2027 (%)
• Exhibit 59: Data Table on Prescription drugs - Year-over-year growth 2022-2027 (%)

• 7.5 Market opportunity by Product 
• Exhibit 60: Market opportunity by Product ($ million)
• Exhibit 61: Data Table on Market opportunity by Product ($ million)

8 Customer Landscape

• 8.1 Customer landscape overview 
• Exhibit 62: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

9 Geographic Landscape

• 9.1 Geographic segmentation 
• Exhibit 63: Chart on Market share by geography 2022-2027 (%)
• Exhibit 64: Data Table on Market share by geography 2022-2027 (%)

• 9.2 Geographic comparison 
• Exhibit 65: Chart on Geographic comparison
• Exhibit 66: Data Table on Geographic comparison

• 9.3 North America - Market size and forecast 2022-2027
• Exhibit 67: Chart on North America - Market size and forecast 2022-2027 ($ million)
• Exhibit 68: Data Table on North America - Market size and forecast 2022-2027 ($ million)
• Exhibit 69: Chart on North America - Year-over-year growth 2022-2027 (%)
• Exhibit 70: Data Table on North America - Year-over-year growth 2022-2027 (%)

• 9.4 Europe - Market size and forecast 2022-2027
• Exhibit 71: Chart on Europe - Market size and forecast 2022-2027 ($ million)
• Exhibit 72: Data Table on Europe - Market size and forecast 2022-2027 ($ million)
• Exhibit 73: Chart on Europe - Year-over-year growth 2022-2027 (%)
• Exhibit 74: Data Table on Europe - Year-over-year growth 2022-2027 (%)

• 9.5 Asia - Market size and forecast 2022-2027
• Exhibit 75: Chart on Asia - Market size and forecast 2022-2027 ($ million)
• Exhibit 76: Data Table on Asia - Market size and forecast 2022-2027 ($ million)
• Exhibit 77: Chart on Asia - Year-over-year growth 2022-2027 (%)
• Exhibit 78: Data Table on Asia - Year-over-year growth 2022-2027 (%)

• 9.6 Rest of World (ROW) - Market size and forecast 2022-2027 
• Exhibit 79: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
• Exhibit 80: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
• Exhibit 81: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
• Exhibit 82: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)

• 9.7 US - Market size and forecast 2022-2027
• Exhibit 83: Chart on US - Market size and forecast 2022-2027 ($ million)
• Exhibit 84: Data Table on US - Market size and forecast 2022-2027 ($ million)
• Exhibit 85: Chart on US - Year-over-year growth 2022-2027 (%)
• Exhibit 86: Data Table on US - Year-over-year growth 2022-2027 (%)

• 9.8 UK - Market size and forecast 2022-2027
• Exhibit 87: Chart on UK - Market size and forecast 2022-2027 ($ million)
• Exhibit 88: Data Table on UK - Market size and forecast 2022-2027 ($ million)
• Exhibit 89: Chart on UK - Year-over-year growth 2022-2027 (%)
• Exhibit 90: Data Table on UK - Year-over-year growth 2022-2027 (%)

• 9.9 Japan - Market size and forecast 2022-2027
• Exhibit 91: Chart on Japan - Market size and forecast 2022-2027 ($ million)
• Exhibit 92: Data Table on Japan - Market size and forecast 2022-2027 ($ million)
• Exhibit 93: Chart on Japan - Year-over-year growth 2022-2027 (%)
• Exhibit 94: Data Table on Japan - Year-over-year growth 2022-2027 (%)

• 9.10 Germany - Market size and forecast 2022-2027
• Exhibit 95: Chart on Germany - Market size and forecast 2022-2027 ($ million)
• Exhibit 96: Data Table on Germany - Market size and forecast 2022-2027 ($ million)
• Exhibit 97: Chart on Germany - Year-over-year growth 2022-2027 (%)
• Exhibit 98: Data Table on Germany - Year-over-year growth 2022-2027 (%)

• 9.11 China - Market size and forecast 2022-2027
• Exhibit 99: Chart on China - Market size and forecast 2022-2027 ($ million)
• Exhibit 100: Data Table on China - Market size and forecast 2022-2027 ($ million)
• Exhibit 101: Chart on China - Year-over-year growth 2022-2027 (%)
• Exhibit 102: Data Table on China - Year-over-year growth 2022-2027 (%)

• 9.12 Market opportunity by geography 
• Exhibit 103: Market opportunity by geography ($ million)
• Exhibit 104: Data Tables on Market opportunity by geography ($ million)

10 Drivers, Challenges, and Trends

• 10.1 Market drivers 

• 10.2 Market challenges 

• 10.3 Impact of drivers and challenges 
• Exhibit 105: Impact of drivers and challenges in 2022 and 2027

• 10.4 Market trends 

11 Vendor Landscape

• 11.1 Overview 

• 11.2 Vendor landscape 
• Exhibit 106: Overview on Criticality of inputs and Factors of differentiation

• 11.3 Landscape disruption 
• Exhibit 107: Overview on factors of disruption

• 11.4 Industry risks 
• Exhibit 108: Impact of key risks on business

12 Vendor Analysis

• 12.1 Vendors covered 
• Exhibit 109: Vendors covered

• 12.2 Market positioning of vendors 
• Exhibit 110: Matrix on vendor position and classification

• 12.3 Abbott Laboratories 
• Exhibit 111: Abbott Laboratories - Overview
• Exhibit 112: Abbott Laboratories - Business segments
• Exhibit 113: Abbott Laboratories - Key news
• Exhibit 114: Abbott Laboratories - Key offerings
• Exhibit 115: Abbott Laboratories - Segment focus

• 12.4 AbbVie Inc. 
• Exhibit 116: AbbVie Inc. - Overview
• Exhibit 117: AbbVie Inc. - Product / Service
• Exhibit 118: AbbVie Inc. - Key news
• Exhibit 119: AbbVie Inc. - Key offerings

• 12.5 AFT Pharmaceuticals Ltd. 
• Exhibit 120: AFT Pharmaceuticals Ltd. - Overview
• Exhibit 121: AFT Pharmaceuticals Ltd. - Business segments
• Exhibit 122: AFT Pharmaceuticals Ltd. - Key offerings
• Exhibit 123: AFT Pharmaceuticals Ltd. - Segment focus

• 12.6 Bausch Health Co. Inc. 
• Exhibit 124: Bausch Health Co. Inc. - Overview
• Exhibit 125: Bausch Health Co. Inc. - Business segments
• Exhibit 126: Bausch Health Co. Inc. - Key news
• Exhibit 127: Bausch Health Co. Inc. - Key offerings
• Exhibit 128: Bausch Health Co. Inc. - Segment focus

• 12.7 I MED Pharma Inc. 
• Exhibit 129: I MED Pharma Inc. - Overview
• Exhibit 130: I MED Pharma Inc. - Product / Service
• Exhibit 131: I MED Pharma Inc. - Key offerings

• 12.8 Johnson and Johnson Services Inc. 
• Exhibit 132: Johnson and Johnson Services Inc. - Overview
• Exhibit 133: Johnson and Johnson Services Inc. - Business segments
• Exhibit 134: Johnson and Johnson Services Inc. - Key news
• Exhibit 135: Johnson and Johnson Services Inc. - Key offerings
• Exhibit 136: Johnson and Johnson Services Inc. - Segment focus

• 12.9 Laboratoires THEA SAS 
• Exhibit 137: Laboratoires THEA SAS - Overview
• Exhibit 138: Laboratoires THEA SAS - Product / Service
• Exhibit 139: Laboratoires THEA SAS - Key offerings

• 12.10 Mitotech SA 
• Exhibit 140: Mitotech SA - Overview
• Exhibit 141: Mitotech SA - Product / Service
• Exhibit 142: Mitotech SA - Key offerings

• 12.11 Novaliq GmbH 
• Exhibit 143: Novaliq GmbH - Overview
• Exhibit 144: Novaliq GmbH - Product / Service
• Exhibit 145: Novaliq GmbH - Key offerings

• 12.12 Novartis AG 
• Exhibit 146: Novartis AG - Overview
• Exhibit 147: Novartis AG - Business segments
• Exhibit 148: Novartis AG - Key offerings
• Exhibit 149: Novartis AG - Segment focus

• 12.13 Oasis Medical Inc. 
• Exhibit 150: Oasis Medical Inc. - Overview
• Exhibit 151: Oasis Medical Inc. - Product / Service
• Exhibit 152: Oasis Medical Inc. - Key offerings

• 12.14 Otsuka Holdings Co. Ltd. 
• Exhibit 153: Otsuka Holdings Co. Ltd. - Overview
• Exhibit 154: Otsuka Holdings Co. Ltd. - Business segments
• Exhibit 155: Otsuka Holdings Co. Ltd. - Key offerings
• Exhibit 156: Otsuka Holdings Co. Ltd. - Segment focus

• 12.15 Santen Pharmaceutical Co. Ltd. 
• Exhibit 157: Santen Pharmaceutical Co. Ltd. - Overview
• Exhibit 158: Santen Pharmaceutical Co. Ltd. - Product / Service
• Exhibit 159: Santen Pharmaceutical Co. Ltd. - Key offerings

• 12.16 Sun Pharmaceutical Industries Ltd.
• Exhibit 160: Sun Pharmaceutical Industries Ltd. - Overview
• Exhibit 161: Sun Pharmaceutical Industries Ltd. - Product / Service
• Exhibit 162: Sun Pharmaceutical Industries Ltd. - Key offerings

• 12.17 Viatris Inc. 
• Exhibit 163: Viatris Inc. - Overview
• Exhibit 164: Viatris Inc. - Business segments
• Exhibit 165: Viatris Inc. - Key news
• Exhibit 166: Viatris Inc. - Key offerings
• Exhibit 167: Viatris Inc. - Segment focus

13 Appendix

• 13.1 Scope of the report 

• 13.2 Inclusions and exclusions checklist
• Exhibit 168: Inclusions checklist
• Exhibit 169: Exclusions checklist

• 13.3 Currency conversion rates for US$ 
• Exhibit 170: Currency conversion rates for US$

• 13.4 Research methodology 
• Exhibit 171: Research methodology
• Exhibit 172: Validation techniques employed for market sizing
• Exhibit 173: Information sources

• 13.5 List of abbreviations 
• Exhibit 174: List of abbreviations

About Us
Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contact
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Website: www.technavio.com

SOURCE Technavio

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED